To: Department of Health and Human Services (HHS) / Centers for Disease Control and Prevention (CDC) / Food and Drug Administration (FDA) / Biomedical Advanced Research and Development Authority (BARDA)

Request:

Requesting any and all internal communications, allocation strategies, trial stratification documents, consent models, or contractor partnerships related to the Novavax COVID-19 vaccine from 2020 to present.

This includes:
	•	Records detailing demographic, behavioral, or medical criteria used to determine Novavax eligibility or access
	•	Allocation models prioritizing specific subpopulations (e.g., immunocompromised, “vaccine-hesitant,” or digital holdouts)
	•	Use of Novavax in comparative surveillance studies involving mRNA-vaccinated vs. protein-subunit-vaccinated populations
	•	Deployment in behavioral segmentation or longitudinal immune modeling cohorts
	•	Communications with pharmacy chains, data brokers, or digital identity platforms regarding Novavax tracking
	•	Internal concerns, objections, or audit findings related to access denial, delayed fulfillment, or selective rollout of Novavax doses

Keywords: Novavax, COVID-19 vaccine, vaccine allocation, behavioral modeling, subpopulation stratification, informed consent, comparative trial, mRNA alternative, BARDA, CDC, immunization access, digital identity linkage, post-market surveillance
